The safety, pharmacokinetics, and distribution in tissue of an amphotericin B (AmB)-cholesteryl sulfate colloidal dispersion (ABCD) were compared with those of micellar amphotericin B-deoxycholate (m-AmB).
The ability of lipid complexes to increase the therapeutic index of amphotericin B (AmB) has been demonstrated in humans (12, 21) and animal models (2, 8, 17) . Improved delivery of active drug to pathogenic fungi or decreased delivery to sites of toxicity in the host may explain this phenomenon, and significant differences have been observed between the pharmacokinetics and the distribution in tissue of AmB-lipid complexes and conventional micellar AmB (m-AmB) (13, 19, 23) .
AmB colloidal dispersion (ABCD), a stable colloidal complex of AmB and cholesteryl sulfate (15) , has been shown to have antifungal activity similar to that of m-AmB in vivo (3a) . We studied the toxicity of ABCD compared with that of m-AmB after 2 weeks of daily administration to beagles, in an attempt to relate differences in the magnitude and localization of AmB toxicities to pharmacokinetic differences between the two dosage forms. Dogs were used in these studies because the toxicology and pharmacokinetics of m-AmB have been described in this species (9, 10, 14) .
(A part of this study was were diluted to the required concentrations with sterile 5% glucose immediately prior to administration. The particle size of reconstituted ABCD, which was measured by dynamic light scattering, was 93 ± 2.0 nm (standard deviation).
Animals. Male (weight, 9.8 to 11 kg) and female (weight, 8.8 to 10.4 kg) beagles approximately 9 months of age (Hazleton-LRE, Kalamazoo, Mich.) were housed according to the standards of National Institutes of Health (15a). One dog of each sex was randomly assigned to one of six groups; the dogs received either ABCD (0.6, 1.2, 2.5, 5.0, or 10.0 mg/kg of body weight per day) or m-AmB (0.6 mg/kg/day). m-AmB was not administered at higher doses because of previously reported intolerance in this species (9 Plasma and CSF samples (0.5 ml) were extracted on a solid-phase column (Bond-Elut C-18, 1 ml) and were then separated on a reversed-phase column (30 cm by 3.9 mm; particle size, 10 ,um) (Waters ,uBondapak C-18) by using a mobile phase of 45% acetonitrile in 2.5 mM disodium EDTA. The AmB peak was detected by UV absorption at 382 nm. The recovery of spiked AmB from plasma was approximately 95%. The assay sensitivity was .5 ng/ml, and the assay was linear across the range of calibration standards (10 to 2,500 ng/ml). Inter-and intraday coefficients of variation were 4% or less between 250 and 2,500 ng/ml and 9.8% at 25 ng/ml.
Tissue samples (0.5 g) were homogenized in methanol (4.5 ml) and were then extracted and separated as described above for the analysis of plasma. 
RESULTS
Survival, body weight, and necropsy. Repeated injections of 10 mg of ABCD per kg/day were not tolerated. Both dogs became moribund, and the male was sacrificed after four doses and the female was sacrificed after seven doses. Both animals exhibited emesis after dosing, severe anorexia, gastrointestinal hemorrhage, and dehydration. All other animals survived the study. Dose-dependent episodes of emesis, diarrhea, and ocular discharge were observed during the second week of dosing in animals that received 0.6 mg of m-AmB per kg/day and 2.5 and 5.0 mg of ABCD per kg/day. Although it was not quantitated, food and water consumption was markedly reduced in these same three groups during the second week of dosing.
All animals lost weight during the study. Those that received 0.6 mg of m-AmB per kg/day lost 2.0 to 2.4 kg by the end of the study, while weight loss in dogs that received ABCD ranged, in a dose-dependent manner, from 0.2 to 0.4 kg (the group that received 0.6 mg/kg/day) to 1.2 to 1.8 kg (the group that received 5 mg/kg/day).
Necropsy revealed signs of hemorrhagic gastritis and enteritis in the group that received 10 mg of ABCD per kg/day and the group that received 0.6 mg of m-AmB per kg/day. In addition, lingual ulcers were observed in both animals dosed with 0.6 mg of m-AmB per kg/day. No clinically significant gross lesions were observed in any of the animals that received 5.0 mg of ABCD per kg/day.
Microscopic pathology. Microscopic pathology observations after 14 doses of 0.6 mg of m-AmB per kg/day and 5.0 mg of ABCD per kg/day and after 4 to 7 doses of 10.0 mg of ABCD per kg/day are summarized in Table 1 .
All six animals in these three groups exhibited mild to moderate renal tubular nephrosis, including degeneration, necrosis, and loss of proximal tubular epithelium. Accumulation of cellular debris in distal tubules caused dilation of proximal tubules. The flattened epithelial cells observed in many tubules represent early repair of denuded basement membranes. Interstitial and intraluminal calcified foci ap- peared as a result of mineralization of injured support and epithelial cells (Fig. 1A) .
All changes observed after ABCD exposure were also observed in the kidneys of dogs exposed to m-AmB. In contrast, kidneys from animals that received 0.6 mg of ABCD per kg/day appeared normal upon microscopic examination (Fig. 1B) .
In addition to these renal effects, minimal to mild hepatocellular fatty changes were observed in dogs that received 0.6 mg of m-AmB per kg/day and 5.0 or 10.0 mg of ABCD per kg/day.
No other microscopic lesions were observed after repeated administration of up to 5.0 mg of ABCD per kg/day.
Mild to marked hemorrhagic gastroenteritis and lymphoid depletion were observed after exposure to 0.6 mg of m-AmB per kg/day and 10 mg of ABCD per kg/day. Alveolitis and hemorrhagic cystitis were also observed in individual animals after exposure to 0.6 mg of m-AmB per kg/day and 10 mg of ABCD per kg/day, respectively. Both Mass balance. Recovery of AmB from the four weighed tissues (liver, spleen, kidneys, and brain) is given in Table 5 . At higher doses (2.5 and 5.0 mg/kg/day) of ABCD, recovery of drug from the liver decreased substantially, but recovery from the spleen and kidneys did not change. While nearly 5% of the total dose was found in the kidneys after administration of 0.6 mg of m-AmB per kg/day, less than 1% was recovered in the kidneys at any dose of ABCD.
Concentration in tissue and target organ toxicity. The relationships between systemic exposure, concentration in tissue, and observed changes in organ-specific clinical chemistry values (11) are presented for two target organs (liver and kidneys) in Fig. 5A and B.
Concentrations of AmB measured in the kidneys appeared to increase with systemic exposure (as measured by plasma AUCO.24 ) for both m-AmB and ABCD (Fig. SA, left) .
Similarly, dose-dependent nephrotoxicity, as reflected by creatinine levels in serum, appeared to be proportional to the concentration of AmB in the kidneys for both formulations (Fig. 5A, right) . Thus, although equal doses of ABCD and m-AmB (0.6 mg/kg) resulted in unequal indications of nephrotoxicity, similar systemic exposures resulted in nephrotoxicity of approximately equal severities for both formulations.
In contrast, concentrations of AmB in liver were much higher in relation to systemic exposure after ABCD exposure than after m-AmB exposure (Fig. SB, left panel) . Also, dose-dependent indications of hepatocyte toxicity, reflected in serum alanine aminotransferase levels, developed at much higher AmB concentrations in liver following ABCD exposure than following m-AmB exposure (Fig. SB, right panel) .
Thus, while animals that received 5 mg of ABCD per kg/day and 0.6 mg of m-AmB per kg/day displayed similar clinical manifestations of hepatotoxicity, concentrations of AmB in liver were seven to nine times higher in the ABCDtreated group. At equivalent doses (0.6 mg/kg/day), AmB levels in liver were lower in the m-AmB group than they were in the ABCD group, yet significant elevations of all three liver specific parameters were observed in m-AmBtreated animals, with no elevations observed in the ABCDtreated animals.
DISCUSSION
Toxicology. Although repeated injections of 10 mg of ABCD per kg/day were not tolerated by dogs, ABCD was considerably safer than the conventional micellar formulation (m-AmB). Dogs tolerated daily injections of 5.0 mg of ABCD per kg/day for 14 consecutive days. Changes in clinical chemistry, pathology, urinalysis, and body weight observed at this dose of ABCD were of no greater severity than those observed in animals dosed with 0.6 mg of m-AmB per kg/day, indicating that ABCD has a safety margin of about eightfold over m-AmB.
The target organs for ABCD toxicity in the dog appeared to be identical to those for m-AmB toxicity. Previous studies disclosed the renal, hepatic, and gastrointestinal effects of AmB in dogs (9) . Similar target organs were observed in the present study for both m-AmB and ABCD.
Pharmacokinetics. At equivalent doses (0.6 mg/kg/day), levels of drug in plasma were lower in ABCD-dosed animals, especially on days 7 and 14. Cmax, Cmin, and AUCO.24 increased throughout the study in the m-AmB-treated group, suggesting that increased systemic exposure occurred as a result of drug accumulation during repeated dosing with m-AmB. The group that received 2.5 mg of ABCD per kg/day experienced an increase in Cmin and AUCO24 during the first week only. Otherwise, Cmax, Cmin, and ALJCO 24 did not increase in the groups treated with 0.6 and 2.5 mg ABCD per kg/day during the study.
These data indicate that steady-state levels in plasma are reached more rapidly after administration of ABCD than after administration of m-AmB. The fact that AUCO, 24 fell from days 1 to 14 in dogs that received 0.6 mg of ABCI per kg per day suggests that AmB clearance increased with time in this group. Thus, steady-state levels in plasma were approached more rapidly than expected from the relatively long terminal half-life of AmB.
The secondary peaks in concentrations in plasma observed in this study indicate an unusual feature of AmB metabolism. This previously unreported phenomenon was observed in all ABCD-treated animals and, with reduced frequency and magnitude, in both m-AmB-treated dogs. A similar phenomenon was observed in a retrospective examination of two previously reported pharmacokinetic studies of AmB in rats (7, 22) .
The rise in the concentration in plasma appeared with diurnal regularity, which was apparently unrelated to the event of dosing, since a similar cycle occurred on day 15, more than 24 h after the final dose. Several mechanisms could account for this cyclic increase in levels in plasma.
Since AmB binds avidly to lipoproteins and sterols, diurnal and/or postprandial increases in circulating lipids could increase the AmB binding capacity in the plasma. Alternately, levels in plasma could rise as a result of cyclic input of drug into the circulation. Since AmB is excreted in the bile (5), enterohepatic cycling could occur, although AmB is poorly absorbed after oral administration (3). Cyclic input could also occur from tissues such as the liver, which contains large amounts of AmB and which secretes lipoproteins which might contain bound AmB. Release of less than 0.5% of the AmB measured in the liver could account for the magnitude of plasma level fluctuations observed in this study. Additional studies are required to determine the mechanism and potential therapeutic implications of these plasma level fluctuations.
Distribution in tissue. Administration of AmB as ABCD reduced the delivery of AmB to two important sites of toxicity in the dog: the kidneys and the gut. The apparent result of this altered distribution is a reduction in the toxicity of ABCD in comparison with that of m-AmB. Dogs tolerated eightfold higher doses of ABCD (5 mg/kg/day) before exhib- iting toxicity of the same severity produced by m-AmB (0.6 mg/kg/day). Our data indicate that diffusion is the driving force for drug uptake by these non-reticuloendothelial system organs, since levels in tissue are proportional to plasma AUC for both formulations of AmB. Thus, the decreased renal and gastrointestinal toxicities of ABCD are probably directly related to the decreased levels in plasma observed after administration of this formulation. While it spared many organs, ABCD increased the delivery of AmB to the organs of the reticuloendothelial system: the liver, spleen, and bone marrow. However, increased concentrations of AmB in the liver and bone marrow as a result of ABCD administration were not accompanied by evidence of increased toxicity in reticuloendothelial system organs. When ABCD was administered, seven-to ninefold higher concentrations were tolerated by the liver than were tolerated after m-AmB administration. These observations indicate that ABCD is actively taken up by the liver, where it remains in a form or location with reduced toxicologic activity.
These data in dogs are similar to those previously obtained in rats, which showed that ABCD is rapidly and quantita- 36, 1992 tively taken up by the liver and that the terminal half-life in plasma appears to be controlled by washout of drug from the liver (7). It was proposed that the liver serves as a reservoir of lipid-complexed AmB, from which the drug is slowly released, giving rise to the observed kinetics in plasma. The high recovery of intact drug from the livers of dogs 48 h after dosing with ABCD suggests that although uptake of ABCD by the liver is rapid, the colloidal drug is not subjected to extensive hepatic metabolism. These results are consistent with the hypothesis that colloidal particles of ABCD are phagocytosed by macrophages in the reticuloendothelial system, with the subsequent release of at least a portion of their AmB (20) . A similar hypothesis was put forward by Ellens et al. (6) to account for the distribution of liposomeencapsulated arabinofuranosylcytosine in the tissues of dogs and mice.
Although the relationship between AmB concentrations in plasma and tissues to antifungal activity has not been clearly established (4), the fact that ABCD is toxicologically less active than m-AmB in both the kidneys and liver could result in diminished antifungal activities in these and other organs. Studies in animals, however, have shown that colloidal AmB maintained the ability to clear Aspergillus fumigatus infections from the liver, kidneys, and lungs of rabbits (16) and Coccidioides immitis infections from the liver, spleen, and lungs of mice (3a) . These studies also suggest that ABCD has a higher therapeutic index than that of m-AmB.
The mechanism(s) by which ABCD and other particulate AmB carriers deliver AmB to fungal cells remains to be determined, but the potential role of phagocytic cells in this process (1) should be investigated further, because our data indicate that large amounts of ABCD may be taken up by these cells. In addition, the potential impact of the reduced AmB levels, which we observed in the brain and CSF after ABCD administration, on its effectiveness against fungal meningitis remains to be investigated.
This study has shown that the increased safety of ABCD is related to the rapid uptake of this colloidal dosage form by the liver. The resulting reduced concentrations in plasma reduce the driving force for delivery of AmB to key sites of toxicity, including the kidneys and gut. The apparent relationship of altered kinetics in plasma to altered distribution in tissue seen with ABCD in this study may aid in the interpretation of human clinical studies of ABCD, where concentrations in tissue are not available. It was recently demonstrated that infusion of 1.5 mg of ABCD per kg produced no signs of nephrotoxicity in humans (18) . This suggests that the disposition of ABCD in humans may be similar to that which we observed in dogs and rats: lower AUCs and peak drug levels in the plasma and target organs leading to the decreased toxicity of AmB in this colloidal dosage form.
